{
    "nct_id": "NCT05297565",
    "official_title": "A Phase 3, Open Label, Randomized, Non-Inferiority Pharmacokinetic Study of Nivolumab Subcutaneous (Nivo SC) Versus Intravenous (Nivo IV) Administration in Participants With Stage IIIA/B/C/D or Stage IV Adjuvant Melanoma Following Complete Resection",
    "inclusion_criteria": "* Stage IIIA/B/C/D or Stage IV melanoma and have histologically confirmed melanoma that is completely surgically resected (free of disease) with negative margins\n* Complete resection performed within 12 weeks prior to randomization or treatment assignment\n* Eastern Cooperative Oncology Group (ECOG) performance status of â‰¤ 1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of uveal or mucosal melanoma\n* Untreated/unresected CNS metastases or leptomeningeal metastases\n* Active, known or suspected autoimmune disease\n* Serious or uncontrolled medical disorder 4 weeks prior to screening\n* Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to randomization or treatment assignment. Participants with history of prior early stage basal/squamous cell skin cancer or non-invasive or in situ cancers that have undergone definitive treatment at any time are eligible\n* Prior immunotherapy treatments for any prior malignancies are not permitted\n\nOther protocol-defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}